Brainsway (NASDAQ:BWAY – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.
Other equities analysts also recently issued reports about the stock. Weiss Ratings raised shares of Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a research report on Friday, April 24th. HC Wainwright lowered their price target on Brainsway from $30.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, March 12th. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Northland Securities set a $15.00 target price on Brainsway in a research report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.00.
Get Our Latest Stock Report on BWAY
Brainsway Stock Up 0.1%
Brainsway (NASDAQ:BWAY – Get Free Report) last announced its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.03. Brainsway had a return on equity of 11.10% and a net margin of 14.62%.The business had revenue of $14.55 million during the quarter, compared to analyst estimates of $14.02 million. On average, analysts expect that Brainsway will post 0.31 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Harel Insurance Investments & Financial Services Ltd. bought a new position in Brainsway in the 1st quarter worth approximately $40,000. Raymond James Financial Inc. bought a new stake in shares of Brainsway during the 2nd quarter valued at $85,000. Bank of America Corp DE acquired a new position in shares of Brainsway in the 3rd quarter valued at $107,000. Royal Bank of Canada grew its holdings in shares of Brainsway by 1,145.9% in the 4th quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock valued at $160,000 after buying an additional 7,735 shares during the period. Finally, Centiva Capital LP acquired a new position in shares of Brainsway in the 3rd quarter valued at $181,000. Institutional investors own 30.11% of the company’s stock.
About Brainsway
Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.
The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.
See Also
- Five stocks we like better than Brainsway
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
